Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 16/2023

16.08.2023 | Research

Exploring the most appropriate lymph node staging system for node-positive breast cancer patients and constructing corresponding survival nomograms

verfasst von: Xiao Huang, Xiangnan Xu, An Xu, Zhou Luo, Chunlian Li, Xueying Wang, Deyuan Fu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 16/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The lymph node (LN) status is a crucial prognostic factor for breast cancer (BC) patients. Our study aimed to compare the predictive capabilities of three different LN staging systems in node-positive BC patients and develop nomograms to predict overall survival (OS).

Methods

We enrolled 71,213 eligible patients from the SEER database, and 667 cases from our hospital were used for external validation. All patients were divided into two groups based on the number of removed lymph nodes (RLNs). The prognostic abilities of pN stage, positive LN ratio (LNR), and log odds of positive LN (LODDS) were compared using the C-indexes and AUC values. LASSO regression was performed to identify significant factors associated with prognosis and develop corresponding nomogram models.

Results

Our study found that LNR had superior predictive performance compared to pN and LODDS among patients with RLNs < 10, while pN performed better in patients with RLNs ≥ 10. In the training set, the nomogram models exhibited excellent clinical applicability, as evidenced by the C-indexes, ROC curves, calibration plots, and decision curve analysis curves. Moreover, the nomogram classification accurately differentiated risk subgroups and improved discrimination. These results were externally validated in the validation cohort.

Conclusion

Physicians should select different LN staging systems based on the number of RLNs. Our novel nomograms demonstrated excellent performance in both internal and external validations, which may assist in patient counseling and guide treatment decision-making.
Literatur
Zurück zum Zitat Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99CrossRefPubMed Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99CrossRefPubMed
Zurück zum Zitat Axelsson CK, Mouridsen HT, Zedeler K (1992) Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish breast cancer cooperative group (DBCG). Eur J Cancer 28(8–9):1415–1418CrossRef Axelsson CK, Mouridsen HT, Zedeler K (1992) Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish breast cancer cooperative group (DBCG). Eur J Cancer 28(8–9):1415–1418CrossRef
Zurück zum Zitat Braunstein LZ, Taghian AG, Niemierko A et al (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 161(1):173–179CrossRefPubMed Braunstein LZ, Taghian AG, Niemierko A et al (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 161(1):173–179CrossRefPubMed
Zurück zum Zitat Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259CrossRefPubMed Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259CrossRefPubMed
Zurück zum Zitat Chang JM, Leung JWT, Moy L, Ha SM, Moon WK (2020) Axillary nodal evaluation in breast cancer: state of the art. Radiology 295(3):500–515CrossRefPubMed Chang JM, Leung JWT, Moy L, Ha SM, Moon WK (2020) Axillary nodal evaluation in breast cancer: state of the art. Radiology 295(3):500–515CrossRefPubMed
Zurück zum Zitat Chen LJ, Chung KP, Chang YJ, Chang YJ (2015) Ratio and log odds of positive lymph nodes in breast cancer patients with mastectomy. Surg Oncol 24(3):239–247CrossRefPubMed Chen LJ, Chung KP, Chang YJ, Chang YJ (2015) Ratio and log odds of positive lymph nodes in breast cancer patients with mastectomy. Surg Oncol 24(3):239–247CrossRefPubMed
Zurück zum Zitat Chu J, Yang D, Wang L, Xia J (2020) Nomograms predicting survival for all four subtypes of breast cancer: a SEER-based population study. Ann Transl Med 8(8):544CrossRefPubMedPubMedCentral Chu J, Yang D, Wang L, Xia J (2020) Nomograms predicting survival for all four subtypes of breast cancer: a SEER-based population study. Ann Transl Med 8(8):544CrossRefPubMedPubMedCentral
Zurück zum Zitat de Glas NA, Kiderlen M, Bastiaannet E et al (2013) Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis. Breast Cancer Res Treat 138(2):561–569CrossRefPubMed de Glas NA, Kiderlen M, Bastiaannet E et al (2013) Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis. Breast Cancer Res Treat 138(2):561–569CrossRefPubMed
Zurück zum Zitat Erbes T, Orlowska-Volk M, Hausen AZ, Rücker G, Mayer S, Voigt M, Farthmann J, Iborra S, Hirschfeld M, Meyer PT et al (2014) Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer 14:4CrossRefPubMedPubMedCentral Erbes T, Orlowska-Volk M, Hausen AZ, Rücker G, Mayer S, Voigt M, Farthmann J, Iborra S, Hirschfeld M, Meyer PT et al (2014) Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer 14:4CrossRefPubMedPubMedCentral
Zurück zum Zitat Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRefPubMedPubMedCentral Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRefPubMedPubMedCentral
Zurück zum Zitat Giuliano AE, Connolly JL, Edge SB et al (2017) Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual [published correction appears in CA Cancer J Clin. 2017 Jul 8;67(4):345]. CA Cancer J Clin 67(4):290–303CrossRefPubMed Giuliano AE, Connolly JL, Edge SB et al (2017) Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual [published correction appears in CA Cancer J Clin. 2017 Jul 8;67(4):345]. CA Cancer J Clin 67(4):290–303CrossRefPubMed
Zurück zum Zitat Huang B, Chen C, Ni M, Mo S, Cai G, Cai S (2016) Log odds of positive lymph nodes is a superior prognostic indicator in stage III rectal cancer patients: a retrospective analysis of 17,632 patients in the SEER database. Int J Surg 32:24–30CrossRefPubMed Huang B, Chen C, Ni M, Mo S, Cai G, Cai S (2016) Log odds of positive lymph nodes is a superior prognostic indicator in stage III rectal cancer patients: a retrospective analysis of 17,632 patients in the SEER database. Int J Surg 32:24–30CrossRefPubMed
Zurück zum Zitat Huang X, Luo Z, Liang W et al (2022) Survival nomogram for young breast cancer patients based on the SEER database and an external validation cohort. Ann Surg Oncol 29(9):5772–5781CrossRefPubMedPubMedCentral Huang X, Luo Z, Liang W et al (2022) Survival nomogram for young breast cancer patients based on the SEER database and an external validation cohort. Ann Surg Oncol 29(9):5772–5781CrossRefPubMedPubMedCentral
Zurück zum Zitat Kustić D, Klarica Gembić T, Grebić D, Petretić Majnarić S, Nekić J (2020) The role of different lymph node staging systems in predicting prognosis and determining indications for postmastectomy radiotherapy in patients with T1–T2pN1 breast carcinoma. Strahlenther Onkol 196(11):1044–1054CrossRefPubMed Kustić D, Klarica Gembić T, Grebić D, Petretić Majnarić S, Nekić J (2020) The role of different lymph node staging systems in predicting prognosis and determining indications for postmastectomy radiotherapy in patients with T1–T2pN1 breast carcinoma. Strahlenther Onkol 196(11):1044–1054CrossRefPubMed
Zurück zum Zitat Lyu MH, Ma YZ, Tian PQ et al (2021) Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis. Chin Med J (Engl) 134(22):2692–2699CrossRefPubMed Lyu MH, Ma YZ, Tian PQ et al (2021) Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis. Chin Med J (Engl) 134(22):2692–2699CrossRefPubMed
Zurück zum Zitat Mandelblatt J (2006) Treating breast cancer: the age old dilemma of old age. J Clin Oncol 24(27):4369–4370CrossRefPubMed Mandelblatt J (2006) Treating breast cancer: the age old dilemma of old age. J Clin Oncol 24(27):4369–4370CrossRefPubMed
Zurück zum Zitat Samiei S, Simons JM, Engelen SME et al (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891CrossRefPubMedPubMedCentral Samiei S, Simons JM, Engelen SME et al (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891CrossRefPubMedPubMedCentral
Zurück zum Zitat Singh D, Mandal A (2020) The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients. Breast Cancer Res Treat 184(3):839–848CrossRefPubMed Singh D, Mandal A (2020) The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients. Breast Cancer Res Treat 184(3):839–848CrossRefPubMed
Zurück zum Zitat Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed
Zurück zum Zitat Tamirisa N, Lin H, Shen Y et al (2020) Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. JAMA Oncol 6(10):1548–1554CrossRefPubMed Tamirisa N, Lin H, Shen Y et al (2020) Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. JAMA Oncol 6(10):1548–1554CrossRefPubMed
Zurück zum Zitat Teng J, Abdygametova A, Du J et al (2020) Bayesian inference of lymph node ratio estimation and survival prognosis for breast cancer patients. IEEE J Biomed Health Inform 24(2):354–364CrossRefPubMed Teng J, Abdygametova A, Du J et al (2020) Bayesian inference of lymph node ratio estimation and survival prognosis for breast cancer patients. IEEE J Biomed Health Inform 24(2):354–364CrossRefPubMed
Zurück zum Zitat Veitch Z, Khan OF, Tilley D et al (2019) Real-world outcomes of adjuvant chemotherapy for node-negative and node-positive HER2-positive breast cancer. J Natl Compr Canc Netw 17(1):47–56CrossRefPubMed Veitch Z, Khan OF, Tilley D et al (2019) Real-world outcomes of adjuvant chemotherapy for node-negative and node-positive HER2-positive breast cancer. J Natl Compr Canc Netw 17(1):47–56CrossRefPubMed
Metadaten
Titel
Exploring the most appropriate lymph node staging system for node-positive breast cancer patients and constructing corresponding survival nomograms
verfasst von
Xiao Huang
Xiangnan Xu
An Xu
Zhou Luo
Chunlian Li
Xueying Wang
Deyuan Fu
Publikationsdatum
16.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 16/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05283-z

Weitere Artikel der Ausgabe 16/2023

Journal of Cancer Research and Clinical Oncology 16/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.